Safety and tolerability of low-dose naltrexone therapy in children with moderate to severe Crohn's disease: A pilot study

Journal of Clinical Gastroenterology

Volumn 47, Issue 4, 2013, Pages 339-345

  Smith, Jill P ^a   Field, Douglas ^b   Bingaman, Sandra I ^a   Evans, Robert ^a   Mauger, David T ^a  

^a PENN STATE COLLEGE OF MEDICINE   (United States)

^b PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

IBD; Low dose naltrexone; Opioid receptors

Indexed keywords

NALTREXONE; PLACEBO;

ADOLESCENT; APPETITE; ARTICLE; BLOOD ANALYSIS; CHILD; CONTROLLED STUDY; CROHN DISEASE; DIPLOPIA; DISEASE ACTIVITY; DISEASE SEVERITY; DREAM; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HAIR LOSS; HEADACHE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; NAUSEA; PAPULE; PEDIATRIC CROHN'S DISEASE ACTIVITY INDEX; PEDIATRICS; PHYSICAL EXAMINATION; PRESCHOOL CHILD; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SCHOOL CHILD; SCORING SYSTEM; SIDE EFFECT; SLEEP DISORDER; TREATMENT DURATION; TWITCHING MOTILITY;

ADMINISTRATION, ORAL; ADOLESCENT; AGE FACTORS; CHILD; CROHN DISEASE; FEMALE; HUMANS; MALE; NALTREXONE; NARCOTIC ANTAGONISTS; PENNSYLVANIA; PILOT PROJECTS; QUALITY OF LIFE; QUESTIONNAIRES; REMISSION INDUCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TREATMENT OUTCOME;

EID: 84875382287     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e3182702f2b     Document Type: Article

References (56)

1. Hyams J, Crandall W, Kugathasan S, et al. Induction and maintenance infliximab therapy for the treatment of moderateto- severe Crohn's disease in children. Gastroenterology. 2007;132:863-873
2. Bell S, Kamm MA. Antibodies to tumour necrosis factor alpha as treatment for Crohn's disease. Lancet. 2000;355:858-860
3. Sandborn WJ, Hanauer SB. Antitumor necrosis factor therapy for inflammatory bowel disease: A review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis. 1999;5:119-133
4. Toruner M, Loftus EV Jr, Harmsen WS, et al. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-936
5. Mackey AC, Green L, Liang LC, et al. Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2007;44:265-267
6. Shale M, Kanfer E, Panaccione R, et al. Hepatosplenic T cell lymphoma in inflammatory bowel disease. Gut. 2008;57: 1639-1641
7. Motil KJ, Grand RJ, Davis-Kraft L, et al. Growth failure in children with inflammatory bowel disease: A prospective study. Gastroenterology. 1993;105:681-691
8. Van Limbergen J, Russell RK, Drummond HE, et al. Definition of phenotypic characteristics of childhood-onset inflammatory bowel disease. Gastroenterology. 2008;135: 1114-1122
9. Undevn1od MA, Bevins CL. Defensin-barbed innate immunity: Clinical associations in the pediatric population. Pediatrics. 2010;125:1237-1247
10. Waldhoer M, Bartlett SE, Whistler JL. Opioid receptors. Annu Rev Biochem. 2004;73:953-990
11. McCarthy L, Wetzel M, Sliker JK, et al. Opioids, opioid receptors, and the immune response. Drug Alcohol Depend. 2001;62:111-123
12. Raynor K, Kong H, Chen Y, et al. Pharmacological characterization of the cloned kappa-, delta-, and mu-opioid receptors. Mol Pharmacol. 1994;45:330-334
13. Parenty G, Appelbe S, Milligan G. CXCR2 chemokine receptor antagonism enhances DOP opioid receptor function via allosteric regulation of the CXCR2-DOP receptor heterodimer. Biochem J. 2008;412:245-256
14. White FA, Bhangoo SK, Miller RJ. Chemokines: Integrators of pain and inflammation. Nat Rev Drug Discov. 2005;4: 834-844
15. Finley MJ, Happel CM, Kaminsky DE, et al. Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression. Cell Immunol. 2008;252:146-154
16. Rogers TJ, Peterson PK. Opioid G protein-coupled receptors: Signals at the crossroads of inflammation. Trends Immunol. 2003;24:116-121
17. Matters GL, Harms JF, McGovern C, et al. The opioid antagonist naltrexone improves murine inflammatory bowel disease. J Immunotoxicol. 2008;5:179-187
18. Smith JP, Stock H, Bingaman S, et al. Low-dose naltrexone therapy improves active Crohn's disease. Am J Gastroenterol. 2007;102:820-828
19. Smith JP, Bingaman SI, Ruggiero F, et al. Therapy with the opioid antagonist naltrexone promotes mucosal healing in active Crohn's disease: A randomized placebo-controlled trial. Dig Dis Sci. 2011;56:2088-2097
20. Hyams JS, Ferry GD, Mandel FS, et al. Development and validation of a pediatric Crohn's disease activity index. J Pediatr Gastroenterol Nutr. 1991;12:439-447
21. Petrakis I, Ralevski E, Nich C, et al. Naltrexone and disulfiram in patients with alcohol dependence and current depression. J Clin Psychopharmacol. 2007;27:160-165
22. Lloyd-Still JD, Green OC. A clinical scoring system for chronic inflammatory bowel disease in children. Dig Dis Sci. 1979;24: 620-624
23. Harvey RF, Bradshaw JM. A simple index of Crohn's-disease activity. Lancet. 1980;1:514
24. Otley A, Smith C, Nicholas D, et al. The IMPACT questionnaire: A valid measure of health-related quality of life in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2002;35:557-563
25. Mitchell JE. Naltrexone and hepatotoxicity. Lancet. 1986;1:1215
26. Yen MH, Ko HC, Tang FI, et al. Study of hepatotoxicity of naltrexone in the treatment of alcoholism. Alcohol. 2006;38: 117-120
27. Eiser C, Morse R. Quality-of-life measures in chronic diseases of childhood. Health Technol Assess. 2001;5:1-157
28. Griffiths AM, Otley AR, Hyams J, et al. A review of activity indices and end points for clinical trials in children with Crohn's disease. Inflamm Bowel Dis. 2005;11:185-196
29. Irvine EJ, Feagan B, Rochon J, et al. Quality of life: A valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn's Relapse Prevention Trial Study Group. Gastroenterology. 1994;106: 287-296
30. Griffiths AM, Nicholas D, Smith C, et al. Development of a quality-of-life index for pediatric inflammatory bowel disease: Dealing with differences related to age and IBD type. J Pediatr Gastroenterol Nutr. 1999;28:S46-S52
31. Lichtenstein GR, Feagan BG, Cohen RD, et al. Serious infections and mortality in association with therapies for Crohn's disease: TREAT registry. Clin Gastroenterol Hepatol. 2006;4:621-630
32. Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn's disease. Am J Gastroenterol. 2005;100:2225-2229
33. Crain SM, Shen K. Enhanced analgesic potency and reduced tolerance of morphine in 129/SvEv mice: Evidence for a deficiency in GM1 ganglioside- regulated excitatory opioid receptor functions. Brain Res. 2000;856:227-235
34. Fioramonti J, Bueno L. Centrally acting agents and visceral sensitivity. Gut. 2002;51(suppl 1):i91-i95
35. Hawkes ND, Rhodes J, Evans BK, et al. Naloxone treatment for irritable bowel syndrome - A randomized controlled trial with an oral formulation. Aliment Pharmacol Ther. 2002;16: 1649-1654
36. Kariv R, Tiomny E, Grenshpon R, et al. Low-dose naltrexone for the treatment of irritable bowel syndrome: A pilot study. Dig Dis Sci. 2006;51:2128-2133
37. Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn's disease. Am J Gastroenterol. 2005;100:2225-2229
38. Crain SM, Shen K. Enhanced analgesic potency and reduced tolerance of morphine in 129/SvEv mice: Evidence for a deficiency in GM1 ganglioside- regulated excitatory opioid receptor functions. Brain Res. 2000;856:227-235
39. Fioramonti J, Bueno L. Centrally acting agents and visceral sensitivity. Gut. 2002;51(suppl 1):i91-i95
40. Hawkes ND, Rhodes J, Evans BK, et al. Naloxone treatment for irritable bowel syndrome - A randomized controlled trial with an oral formulation. Aliment Pharmacol Ther. 2002;16: 1649-1654
41. Kariv R, Tiomny E, Grenshpon R, et al. Low-dose naltrexone for the treatment of irritable bowel syndrome: A pilot study. Dig Dis Sci. 2006;51:2128-2133
42. Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn's disease. Am J Gastroenterol. 2005;100:2225-2229
43. Crain SM, Shen K. Enhanced analgesic potency and reduced tolerance of morphine in 129/SvEv mice: Evidence for a deficiency in GM1 ganglioside- regulated excitatory opioid receptor functions. Brain Res. 2000;856:227-235
44. Fioramonti J, Bueno L. Centrally acting agents and visceral sensitivity. Gut. 2002;51(suppl 1):i91-i95
45. Hawkes ND, Rhodes J, Evans BK, et al. Naloxone treatment for irritable bowel syndrome - A randomized controlled trial with an oral formulation. Aliment Pharmacol Ther. 2002;16: 1649-1654
46. Kariv R, Tiomny E, Grenshpon R, et al. Low-dose naltrexone for the treatment of irritable bowel syndrome: A pilot study. Dig Dis Sci. 2006;51:2128-2133
47. Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn's disease. Am J Gastroenterol. 2005;100:2225-2229
48. Crain SM, Shen K. Enhanced analgesic potency and reduced tolerance of morphine in 129/SvEv mice: Evidence for a deficiency in GM1 ganglioside- regulated excitatory opioid receptor functions. Brain Res. 2000;856:227-235
49. Fioramonti J, Bueno L. Centrally acting agents and visceral sensitivity. Gut. 2002;51(suppl 1):i91-i95
50. Hawkes ND, Rhodes J, Evans BK, et al. Naloxone treatment for irritable bowel syndrome - A randomized controlled trial with an oral formulation. Aliment Pharmacol Ther. 2002;16: 1649-1654
51. Kariv R, Tiomny E, Grenshpon R, et al. Low-dose naltrexone for the treatment of irritable bowel syndrome: A pilot study. Dig Dis Sci. 2006;51:2128-2133
52. Cross RK, Wilson KT, Binion DG. Narcotic use in patients with Crohn's disease. Am J Gastroenterol. 2005;100:2225-2229
53. Crain SM, Shen K. Enhanced analgesic potency and reduced tolerance of morphine in 129/SvEv mice: Evidence for a deficiency in GM1 ganglioside- regulated excitatory opioid receptor functions. Brain Res. 2000;856:227-235
54. Fioramonti J, Bueno L. Centrally acting agents and visceral sensitivity. Gut. 2002;51(suppl 1):i91-i95
55. Hawkes ND, Rhodes J, Evans BK, et al. Naloxone treatment for irritable bowel syndrome - A randomized controlled trial with an oral formulation. Aliment Pharmacol Ther. 2002;16: 1649-1654
56. Kariv R, Tiomny E, Grenshpon R, et al. Low-dose naltrexone for the treatment of irritable bowel syndrome: A pilot study. Dig Dis Sci. 2006;51:2128-2133